April 13, 2021


Advances in world technology

Substantial progress produced in new COVID-19 vaccine designed by the team of Prof Salanti

STOCKHOLM, Jan. 13, 2021 /PRNewswire/ — On Tuesday January 12th, in Mother nature Communications, solid...

STOCKHOLM, Jan. 13, 2021 /PRNewswire/ — On Tuesday January 12th, in Mother nature Communications, solid preclinical success for a new COVID-19 vaccine, created by the crew of Prof. Salanti from College of Copenhagen, ExpreS2ion Biotech, its joint enterprise companion AdaptVac and the Prevent-nCoV consortium, was printed. Dependent on these benefits, a medical trial application (CTA) for a clinical Section I/II research for the COVID-19 vaccine has been submitted.

About the preclinical benefits
Readouts from the info show that ABNCoV2 has the prospective to be the finest-in-course COVID-19 vaccine with a far more than 100-fold bigger stage of neutralizing antibodies in contrast with printed preclinical animal information from currently accredited COVID-19 vaccines, these kinds of as Pfizer-BioNTech’s, Moderna’s, and AstraZeneca-Oxford’s vaccines. The comprehensive paper is accessible on the internet and can be examine in this article.

About the CTA
The Clinical trial application (CTA) for the ABNCoV2 capsid virus-like particle (cVLP) primarily based COVID-19 vaccine was submitted to the Central Committee on Study Involving Human Subjects (CCMO) in the Netherlands past week. It is predicted to be accepted below a COVID-19 speedy-observe evaluate development. This can be noticed as a further substantial milestone adhering to the November 2020 announcement of the profitable GMP manufacturing of the vaccine. ExpreS2ion expects to current preliminary clinical Section I/IIa success prior to finish of Q1 2021.

Attana’s involvement
Considering that March 2020, Attana has been helping the group of Prof. Ali Salanti at the University of Copenhagen in the development of this COVID-19 vaccine with two of Attana’s QCM Biosensors mixed with exploration intelligence. As can be found in the paper printed, Attana’s know-how has foremost been utilized to analyze kinetic interactions between RBD antigens and CLP-RBD to hACE2. Also, Attana and ExpreS2ion lately proven a strategic partnership which includes a offer arrangement of proteins. In addition, Attana technologies has been made use of to top quality command the vaccine for the IND submission.

Attana CEO Teodor Aastrup remarks:
“I’m thrilled for our partners sake and for the potential of vaccine improvement and want to congratulate all get-togethers included for reaching these kinds of enjoyable results. I am now hunting forward to take a look at this collaboration further more and to with any luck , get the job done additional carefully with both equally Prof. Salanti and the crew at ExpreS2ion in the in the vicinity of time potential.”

For extra details, be sure to call:

Teodor Aastrup
[email protected]
+46 () 8 674 57 00

The Board of administrators for Attana think about that the information in this push launch is not likely to have a substantial effect on the share rate but is of basic fascination for the shareholders and therefore should be communicated.

About Attana

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo problems. Since then, Attana has produced proprietary label free of charge biosensors for biochemical, crude, sera, and cell-centered assays and the Attana Virus Analytics (AVA) platform, a proprietary in-vitro diagnostics (IVD) resource. Attana merchandise and study expert services are employed by Huge Pharma, biotech firms and academic institutions within the daily life sciences. To discover extra about our most recent products and services and merchandise, please pay a visit to www.attana.se or get hold of [email protected]

This info was introduced to you by Cision http://news.cision.com


The subsequent documents are readily available for download: